

AtomVie inks strategic partnership with Jubilant Radiopharma to strengthen logistics and distribution in Clinical Trials

October 16, 2026 | News

Agreement is intended to help optimise the supply of clinical sites



AtomVie Global Radiopharma, a global contract developer and manufacturer (CDMO) for radiopharmaceuticals, has announced a strategic partnership with Jubilant DraxImage Inc., trading as Jubilant Radiopharma (a division of India-based Jubilant Pharmova), to provide logistics, regulatory and last-mile distribution services to support AtomVie's growing portfolio of radiopharmaceuticals programmes. The cooperation is governed by an agreement on logistics and registration services between the two companies.

As part of this partnership, Jubilant Radiopharma will support the acceptance, processing, regulatory compliance and last-mile distribution of the radiopharmaceuticals manufactured by AtomVie through its US pharmacy network. The agreement is intended to help optimise the supply of clinical sites while maintaining the high standards of quality, safety and regulatory compliance required for radiopharmaceutical products.

"With continued growth in the radiopharmaceutical sector, building strong logistics and distribution capabilities is essential to ensure patients and clinical sites receive products reliably and efficiently," said Bruno Paquin, Chief Executive Officer of AtomVie.

Harsher Singh, Chief Executive Officer of Jubilant Radiopharma said, "As a trusted partner for therapeutic clinical trials and go-to-market, we provide the specialised infrastructure, regulatory expertise, therapeutic delivery capabilities, and nationwide supply network needed to support radiopharmaceuticals throughout their lifecycle. Our collaboration with AtomVie reflects our shared commitment to accelerate innovation and expand patient access to the next generation of radiopharmaceutical therapies."